Clinical Trials Sponsored by Bristol-Myers Squibb

Total 2672 results

Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)

Non-Small Cell Lung Cancer

Italy, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Ireland, Japan, Mexico, Poland, Romania, Russian Federation, Spain, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque Psoriasis

Psoriasis

China
Bristol-Myers Squibb

Active, not recruiting

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

Neoplasms by Site

United States, Mexico, Italy, Argentina, Brazil, Chile, France, Netherlands, New Zealand, Poland, Spain, United Kingdom
Bristol-Myers Squibb

Completed

Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation (ARISTOPHANES)

Non-Valvular Atrial Fibrillation

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Rheumatoid Arthritis

Italy, United States, Germany, Argentina, Australia, Czechia, France, Japan, Mexico, Poland, Spain, Switzerland, Taiwan, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Pulmonary Fibrosis

Canada, France, United States, Argentina, Australia, Belgium, Brazil, Chile, China, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Spain, Taiwan, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Advanced Cancer

Italy, Australia, United States, Spain, Romania, Argentina, Canada, Chile, Finland, Germany, Poland
Bristol-Myers Squibb

Active, not recruiting

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE)

Psoriasis

China, Taiwan, Spain, United States, Hungary, Canada, Germany, Japan, Australia, Poland, Czechia, United Kingdom, Korea, Republic of, Israel, New Zealand, Sweden, France, Finland, Russian Federation, Puerto Rico
Bristol-Myers Squibb

Terminated

A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Active, not recruiting

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Leukemia

France, India, United States, Canada, Spain, Italy, Mexico, South Africa, United Kingdom, Korea, Republic of, Russian Federation, Australia, Argentina, Germany, Brazil, Netherlands, Romania, Singapore
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Melanoma | Non-Small Cell Lung Cancer | Advanced Cancer

Canada, United States, Australia, France, Italy, Spain, Finland, Germany, Norway, Poland, Sweden
Bristol-Myers Squibb

Terminated

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

Healthy Participants | Primary Sjögren's Syndrome

Germany, United States
Bristol-Myers Squibb

Completed

A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants

Healthy Participants

China
Bristol-Myers Squibb

Completed

A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study Evaluating Quality of Life for Participants With Atrial Fibrillation (AF) Following a Bleed (EQUAL-AF) (EQUAL-AF)

Atrial Fibrillation

United Kingdom
Bristol-Myers Squibb

Completed

Taste Assessment of Ozanimod

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure

Multiple Myeloma

United States
Bristol-Myers Squibb

Completed

A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Bristol-Myers Squibb

Terminated

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder (CheckMate 9UT)

Urinary Bladder Neoplasms

United States, Argentina, Australia, Brazil, Canada, Chile, China, France, Mexico, Netherlands, Spain, United Kingdom, Italy, Hong Kong, Russian Federation
Bristol-Myers Squibb

Active, not recruiting

A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy (LIST)

Lung Cancer

France
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy (VALOR-HCM)

HOCM, Hypertrophic Obstructive Cardiomyopathy

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

Lupus Erythematosus, Cutaneous

Germany
Bristol-Myers Squibb

Completed

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 714)

Head and Neck Cancer

United States, Brazil, Italy, South Africa, Spain, Canada, Argentina, Belgium, Chile, Czechia, Finland, France, Ireland, Mexico, Netherlands, Norway, Romania, Russian Federation, Sweden, Turkey, United Kingdom
Bristol-Myers Squibb

Completed

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

Cancer

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Chronic Phase Chronic Myeloid Leukemia

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Active, not recruiting

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety (ORION)

Multiple Sclerosis, Relapsing-Remitting

United States
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis

Psoriasis

Japan
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920)

Renal Cell Carcinoma

United States
Bristol-Myers Squibb

Completed

A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions

Healthy Participants

United States
Bristol-Myers Squibb

Terminated

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Lupus Nephritis

United States, Taiwan, Spain, United Kingdom, Netherlands, Germany, China, Australia, Belgium, Mexico, Korea, Republic of, Czechia, Russian Federation, Israel, Canada, Italy
Bristol-Myers Squibb

Completed

A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer (mCRC)

United States
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066)

Melanoma

Canada, Australia, Germany, Italy, Poland, France, Denmark, Argentina, Chile, Spain, Norway, Israel, Sweden, Mexico, Greece, Finland
Bristol-Myers Squibb

Completed

A Study of Adjuvant Melanoma Stakeholder Treatment Preferences

Melanoma

Australia
Bristol-Myers Squibb

Completed

Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab

Encephalitis

United States
Bristol-Myers Squibb

Withdrawn

Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)

Non-valvular Atrial Fibrillation

United States
Bristol-Myers Squibb

Completed

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Melanoma

France, Canada, United States, Germany, Australia, Russian Federation, Spain, Italy, Netherlands, Poland, Denmark, Israel, United Kingdom
Bristol-Myers Squibb

Completed

Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database

Advanced Melanoma

Germany
Bristol-Myers Squibb

Completed

Study of BMS-986158 in Subjects With Select Advanced Cancers (BET)

Advanced Tumors

United States, France, Australia, Spain, Canada
Bristol-Myers Squibb

Active, not recruiting

A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database (DANBIO)

Rheumatoid Arthritis (RA) | Psoriatic Arthritis (PsA)

United States
Bristol-Myers Squibb

Completed

Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment (DCE)

Psoriasis

United States
Bristol-Myers Squibb

Completed

A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan

Psoriasis

Japan

3

Subscribe